Except for inhibitors targeting nonkinase cellular proteins (e.g., mutated KRAS and proteasome) or epigenetic modulators (e.g., histone deacetylases), most SMKIs suppress protein kinases involved in the transformation, growth, proliferation, and survival of cancer cells. Here, KRAS is linked to cancer.